Demonstrating the value of medical technologies
Accelerate your growth
The Deloitte Health Economics and Outcomes Research Group

Demonstrating the value of medical technologies is necessary as a result of regulation and market demand. Due to the multiple dynamics of market access, to meet these requirements, the value of an innovative medical technology needs to be demonstrated to all the stakeholders.

This means that healthcare and biopharmaceutical companies need to generate the value of a product prior to launch, ascertain and enhance that value during launch and maintain that value throughout the lifecycle of the product, both additionally and comparatively.

<table>
<thead>
<tr>
<th>Unmet need</th>
<th>Clinical development phase</th>
<th>Post-launch</th>
</tr>
</thead>
<tbody>
<tr>
<td>Early development</td>
<td>Pre-market development</td>
<td>Market approval</td>
</tr>
</tbody>
</table>

**Generate Value**

### Activities and service offerings

The Deloitte Health Economics and Outcomes Research Group combines the strategic life science and healthcare expertise with the cutting edge technical capabilities originated from robust application of theory and practical experience, therefore we know that to put a new product in the market, it is important to identify and demonstrate value (additionally and comparatively) throughout its lifecycle. Our group focuses on 3 main areas of service provision to address all value needs, from development through to post-launch marketing activities.

**Starting position**

- L1 - Portfolio assessment and R&D analytics
- L2 - Target markets and populations
- L3 - Launch preparation

**Market access strategy**

- M1 - Analyze market access landscape of countries
- M2 - Build value proposition for different stakeholders
- M3 - Build market access strategy and roadmap

**Evidence strategy**

- D1 - Evaluate the design of the evidence strategy
- D2 - Help conduct RWE assessments
- D3 - Evaluate RWE partnership options

**Go-to market strategy**

- P1 - Develop marketing strategy
- P2 - Develop pricing strategy and price setting
- P3 - Estimate sales potential

**Reimbursement**

- M4 - Develop HTA and reimbursement submissions
- M5 - Country specific reimbursement support
- M6 - Support conditional reimbursement options

**Go-to market implementation (internal or with distributor)**

- I1 - Strategic marketing
- I2 - Service model
- I3 - Targeting and segmentation
- I4 - Sales pilot and Sales force effectiveness

**Support services**

- L - Launch
- M - Market Access
- D - Data
- P - Pricing
- I - Implementation

*Network would include academics, KOL’s, provider organisations, patient organisations, payers, purchasing organisations, distributors and other relevant stakeholders*
Generating value

The potential and value of a new technology is determined by its characteristics, but also by value creation. The market “sweet spot” of a product can be either identified or determined, and many activities, across different fronts can support you in this journey, either if you want to bring it to the market, or turn it into an investment opportunity.

<table>
<thead>
<tr>
<th>Unmet need</th>
<th>Clinical development phase</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Early development</td>
</tr>
<tr>
<td></td>
<td>Pre-market development</td>
</tr>
</tbody>
</table>

Generate Value

Why perform a literature review?
- Due diligence
- Portfolio assessment
- Patent value assessment
- Licensing of new technologies
- Market and landscape assessment - to determine country launch sequencing
- Pricing strategy and assessment - reference pricing, value based pricing
- Evidence synthesis
- Burden of illness studies
- Epidemiology studies
- Indirect and Mixed Treatment Comparisons
- Global value dossier - elaboration and refinement
- Value story and value messaging - elaboration, testing and refinement
- Development of peer-reviewed publications - economic models, evidence based studies
- Literature reviews
- Policy white papers
- Advisory boards - any scope and focus area across the lifecycle
- Expert/Patient panels
- Corporate training on health economics - recommended especially for new biotechs/ start-ups

Technology Valuation and Portfolio Assessment

- Scientific Research
- Market Access assessment
- Forecast if approved
- Probability of success
- Required Investment

A compound portfolio assessment of target companies/technologies

Example engagement
A private equity firm is planning to invest in a small innovative pharmaceutical company. Deloitte helped to assess the financial potential of the portfolio and probability of success to estimate the future value of the company.

Global Value Dossiers

- Current disease burden
- Product’s added value
- Economic value
- Communicatie

Example engagement
A large device company developed a technology for renal denervation to treat drug-resistant hypertensive patients. Deloitte built a robust value dossier and budget impact model for both reimbursement and commercial purposes.

Advisory Board

It Matters For

- Government
- Payers
- Experts
- Users

- Trends and policies
- Budget constraints
- Health economics
- Pricing and reimbursement assessment
- Innovation potential
- Technology usage
- Experience with product
- Patient needs and views

Engaging experts who can provide ideas and feedback to a company. Advisory boards are well established across all stages of product development and commercialisation.

Example engagement
A leading biotechnology company was seeking specific insights for an innovative oncology product across several European countries. The focus was on the appropriate methodology and assumptions for its indirect comparison and economic models in each market. Deloitte organised a series of cross-country advisory boards (including moderation and handout exercises) indicating the pros and cons of the advisors’ suggestions from a market access, product, and company perspective.
Commercialization / Market launch

Deloitte can help you plan and achieve your market access targets with strategic insights from our internal and external experts. In addition the team has a solid experience with pricing and reimbursement dossiers and economic models, designed according to the needs of each country’s respective authority.

Post-launch

An ever changing landscape and strong competition amongst assets adds a layer of complexity to a product’s post-launch phase, requiring companies to continue gathering data evidence, reviewing and re-creating the technology.

Contacts

For more information, please contact:

R. Ömer Saka MD, MSc
Partner
HEOR Group
T: +32 2 749 57 32
M: +32 473 33 54 27
rsaka@deloitte.com

Edith L. Maes, DBA, MHSM
Director
HEOR Group
T: + 32 2 600 62 42
M: 32 471 63 60 96
emaes@deloitte.com

Barri Falk
Partner
Life Science Strategy
T: +41 58 279 65 56
M: +41 79 228 97 16
barrifalk@deloitte.ch

Deloitte refers to one or more of Deloitte Touche Tohmatsu Limited, a UK private company limited by guarantee ("DTTL"), its network of member firms, and their related entities. DTTL and each of its member firms are legally separate and independent entities. DTTL (also referred to as "Deloitte Global") does not provide services to clients. Please see www.deloitte.com/about for a more detailed description of DTTL and its member firms.

Deloitte provides audit, tax and legal, consulting, and financial advisory services to public and private clients spanning multiple industries. With a globally connected network of member firms in more than 150 countries, Deloitte brings world-class capabilities and high-quality service to clients, delivering the insights they need to address their most complex business challenges. Deloitte has in the region of 200,000 professionals, all committed to becoming the standard of excellence.

This publication contains general information only, and none of Deloitte Touche Tohmatsu Limited, its member firms, or their related entities (collectively, the “Deloitte Network”) is, by means of this publication, rendering professional advice or services. Before making any decision or taking any action that may affect your finances or your business, you should consult a qualified professional adviser. No entity in the Deloitte Network shall be responsible for any loss whatsoever sustained by any person who relies on this publication.

© May 2015 Deloitte Consulting
Designed and produced by the Creative Studio at Deloitte, Belgium.